Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography.

Abstract

Both MR imaging and scintimammography are useful in the evaluation of breast cancer. MR imaging is more sensitive and as specific as scintimammography.

Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MRI Screening: a Meta-analysis

“…Results of "no" on item 6 were shown in seven studies (Stomper et al 1995;Helbich et al 1997;Goerres et al 2003;Kneeshaw et al 2006;Pediconi et al 2007;Woodhams et al 2010;Luciani et al 2011) and no report in one study (Martincich et al 2011). No report on item 11 and item 14 was found in six studies (Fenlon et al 1997;Fischer et al 1999;Alamo et al 2001;Goerres et al 2003;Sardanelli et al 2005;Woodhams et al 2010) and two studies (Fobben et al 1995;Stomper et al 1995) respectively.…”

“…Because the dosage unit of contrast media can't be translated, that is to say, the absolute difference on dosage among these studies is unknown, 2 articles were rejected. 17 studies (Fobben et al, 1995;Stomper et al, 1995;Fenlon et al, 1997;Helbich et al, 1997;Fischer et al, 1999;Alamo et al, 2001;Kawashima et al, 2001;Goerres et al, 2003;Knopp et al, 2003;Pediconi et al, 2005;Sardanelli et al, 2005;Kneeshaw et al, 2006;Pediconi et al, 2007;Pediconi et al, 2008;Woodhams et al, 2010;Luciani et al, 2011;Martincich et al, 2011) with 1934 patients were included based on the inclusion criteria and the data integrity.…”

“…Four references (Knopp et al 2003;Pediconi et al 2005;Pediconi et al 2008;Martincich et al 2011) reported available data on these two agents. Three references (Sardanelli et al 2005;Pediconi et al 2007;Luciani et al 2011) only reported relevant data on gadobenate dimeglumine, and ten studies (Fobben et al 1995;Stomper et al 1995;Fenlon et al 1997;Helbich et Table 2…”

99mTc-Sestamibi Scintimammography

“…In only four of the cited studies applied doses were below the recommended minimal dose of 740 MBq, in none of the studies, higher doses as recommended were applied (1,110 MBq). [47] Europe Turkey 740 Becherer [48] Europe Austria 630-740 Buscombe [49] Europe UK 740 Buscombe [50] Europe UK 740 Cwikla [51] Europe UK 740 Cwikla [52] Europe UK 740 Cwikla [53] Europe UK 740 Fondrinier [54] Europe France 740 Helbich [55] Europe Austria 629-740 Imbriaco [56] Europe Italy 555 Maffioli [57] Europe Italy 740 Marshall [58] Europe UK 750 Mathieu [59] Europe Belgium 740 Maublant [60] Europe France 740 Moretti [19] Europe France 500 Myslivecek [61] Europe Czech Republic 740 Palmedo [62] Europe Germany 740 Palmedo [63] Europe Germany 740 Papantoniou [64] Europe Greece 925-1,110 Prats [65] Europe Spain 740 Prats [66] Europe Spain 740 Sanidas [67] Europe Greece 740 Tiling [68] Europe Germany 740 Tiling [69] Europe Germany 740 Uriarte [70] Europe Spain 740 Chen [71] Asia China 740 Kao [72] Asia Taiwan 740 Kim [73] Asia South Korea 750 Kim [74] Asia South Korea 925 Kim [75] Asia South Korea 750 Tc-Sestamibi Scintimammography…”

Molecular Imaging in Breast Cancer – Potential Future Aspects

“…Nuclear-medical methods for breast imaging have existed since the early 1990s, when it was discovered that the radiotracer technetium-99m (99mTc) sestamibi can be used to image breast cancer with a technique called scintimammography, acquiring images similar to mammography in the craniocaudal (CC) and mediolateral-oblique (MLO) projection [3,4]. The use of 99mTc sestamibi for breast cancer detection was reported by Aktolun et al [5] in 1992 during its evaluation as cardiac imaging agent.…”